# Delcath Systems Inc. (DCTH) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Medical Devices & Supplies. Price $14.40, market value $500 million.

## Valuation
- **P/E (trailing): 1440.0×** (5-yr avg 144.3×, 3-yr avg 144.3×). Delcath Systems Inc. trades at 1440.0× trailing earnings, well above its own five-year average of 144.3×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 338.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 3.15**. A PEG of 3.15 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 5.2×**. Each dollar of revenue is priced at 5.2×.
- **Price / book: 4.1×**. The shares trade at 4.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 3.5%** (5-yr avg -33.3%). Free cash flow equals 3.5% of the market value, above its five-year average of -33.3%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 0.1%**. The inverse of the P/E: 0.1% of the price is earned each year.

## Profitability
- **Gross margin: 87.1%**. Delcath Systems Inc. keeps 87.1% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -1.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: 3.2%**. 3.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 2.4%**. 2.4% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: -2.1%**. Return on all capital, debt included, is -2.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 0.4%**. Each dollar of assets produces 0.4% of profit.

## Growth
- **Revenue growth (1 yr): 129.1%** (3-yr 215.3%/yr). Revenue grew 129.1% over the last year.
- **EPS growth (1 yr): 107.5%**. Earnings per share rose 107.5%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Current ratio: 10.92** (quick 10.92). Current assets cover the next year's liabilities 10.92 times.
- **Altman Z-score: 27.17**. A Z-score of 27.17 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Delcath Systems Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 45.4%** (YTD 41.5%, 3-mo 9.6%). The shares are up 45.4% over twelve months including dividends.
- **From 52-week high: -17.3%** (77.3% above the low). Trading 17% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 1.36** (volatility 50%). Beta of 1.36 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DCTH · Page: https://foliofundamentals.com/stocks/dcth

Not investment advice.